CNSP

CNS Pharmaceuticals, Inc. (CNSP) - 10-K Summary

Business Context and Reporting Period

Reporting Period: Fiscal year ended December 31, 2025.

Company Overview: CNS Pharmaceuticals is a biotechnology company that has executed a strategic pivot. Historically focused on glioblastoma multiforme (GBM), the Company announced a new corporate growth strategy in March 2026 to build a high-value pipeline in neurology and oncology. Consequently, it is exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.

Leadership Changes: The Company appointed Rami Levin as President & CEO effective January 1, 2026. A new executive team, including a new CFO, CMO, CBO, and CTO, was appointed effective March 2, 2026, to execute the new strategy.

Key Financial Metrics

Note: The Company has not generated any revenue from product sales and does not expect to do so until regulatory approval and commercialization are achieved.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by approximately $1.0 million (6.7%) year-over-year, primarily driven by increased Research and Development (R&D) expenses.
• R&D Expenses: Increased from $9.29 million in 2024 to $9.77 million in 2025. This was due to expenditures preparing for a TPI 287 trial and drug manufacturing, partially offset by a decline in Berubicin trial costs.
• General and Administrative (G&A) Expenses: Increased from $5.61 million to $6.21 million, driven by higher employee compensation ($913k increase) and travel expenses, offset by a decrease in stock-based compensation.
• Financing Activities: The Company raised approximately $14.0 million in net proceeds from the sale of common stock in 2025, compared to $23.4 million in 2024. This included sales under an ATM agreement and a public offering in May 2025.
• Stock Splits: The Company effected multiple reverse stock splits in 2024 and 2025 (1-for-50, 1-for-50, and 1-for-12) to maintain compliance with listing requirements.

Guidance, Outlook, Risks, and Contingencies

• Going Concern: The independent auditors have expressed substantial doubt about the Company's ability to continue as a going concern due to recurring losses and negative cash flows. Management estimates current cash will fund operations into the third quarter of 2026.
• Capital Needs: The Company will require significant additional capital to execute its new strategy of in-licensing assets and advancing clinical development. There is no assurance that financing will be available on acceptable terms.
• Internal Controls: Management concluded that internal controls over financial reporting were ineffective as of December 31, 2025, citing material weaknesses related to a lack of segregation of duties, limited access to timely cost information from third-party CROs, and lack of formal documentation.
• Strategic Pivot: The Company is actively searching for new assets in neurology and oncology. It intends to out-license TPI 287 and Berubicin, though there is no assurance these transactions will be completed.
• Intellectual Property: Patents for TPI 287 expire in 2028. Berubicin has no licensed patents but holds Orphan Drug Designation (ODD). The Company is exploring additional patent filings.

Investor Verification Checklist

• Liquidity Runway: Verify the accuracy of the management estimate that cash on hand ($7.2M) will sustain operations only through Q3 2026.
• Financing Plans: Assess the feasibility of raising the substantial capital required for the new asset acquisition strategy given the "going concern" warning and recent stock dilution.
• Out-Licensing Progress: Monitor updates on the potential out-licensing of TPI 287 and Berubicin, as failure to monetize these assets could accelerate cash burn.
• Internal Control Remediation: Review subsequent filings for progress in remediating the material weaknesses in internal controls over financial reporting.
• Asset Acquisition: Track the timeline and terms of any new in-licensing deals, as the Company's future value depends entirely on securing new pipeline assets.